Why Haemonetics Stock Was on Fire Thursday
Key Points
It was something of an outlier in booking gains on a bearish day for stocks overall.
This was the result of an investor-pleasing quarterly earnings report.
- 10 stocks we like better than Haemonetics ›
Niche healthcare stock Haemonetics (NYSE: HAE) was a winner among the clutch of publicly traded companies reporting quarterly earnings on Thursday. On the back of an estimates-beating second quarter of fiscal 2026, investors piled into its shares to push them in excess of 32% higher. That looked particularly impressive next to the bellwether S&P 500's (SNPINDEX: ^GSPC) 1.1% drop that trading session. On Friday, the rally continued, as the stock was up by over 3% that morning.
A tale of two fundamentals
Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst expectation of under $312 million.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
Happily, the company's net income not according to generally accepted accounting principles (so, it was adjusted) veered in the other direction. It climbed more than 5% higher to slightly over $60 million, or $1.27 per share. This too bettered the pundit consensus, which was $1.11.
In its earnings release, Haemonetics quoted CEO Chris Simon as saying the results "demonstrate disciplined execution and increasingly profitable growth across our business."
Revenue guidance lifted
Compounding the twin beats, Haemonetics also adjusted its full-year fiscal 2026 revenue and earnings guidance. For the former, it now feels that the metric will see a decline of 1% to growth of 2% over the 2025 number; previously it was guiding for a drop of 2% to a rise of 1%.
Management also lifted the low end of non-GAAP (adjusted) net income, which should be $4.80 to $5.00 per share for the year. The average analyst estimate is $4.83. The former range was $4.70 to $5.00.
Haemonetics is an under-the-radar niche healthcare company that's getting some investor love with its impressive quarter. As a profitable and growing business, it's certainly worth a look for value investors.
Should you invest $1,000 in Haemonetics right now?
Before you buy stock in Haemonetics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Haemonetics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $591,613!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,152,905!*
Now, it’s worth noting Stock Advisor’s total average return is 1,034% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 3, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
